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Abstract
Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis
(RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with
differences in RA phenotypes. We aimed to assess the prevalence of baseline ACPA reactivities in an inception
cohort of patients with early RA, and to investigate their associations with disease activity, treatment response,
ultrasound findings and radiographic damage.
Methods: Disease-modifying antirheumatic drug (DMARD)-naïve patients with early RA, classified according to the
2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, were included in
the ARCTIC trial and assessed in the present analysis. During follow up, patients were monitored frequently and treatment
was adjusted according to a predetermined protocol, starting with methotrexate monotherapy with prednisolone
bridging. Analysis of 16 different ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase,
vimentin, filaggrin and histone was performed using a multiplex chip-based assay. Samples from 0, 3, 12 and 24 months
were analysed. Controls were blood donors with similar characteristics to the patients (age, gender, smoking status).
Results: A total of 217 patients and 94 controls were included. Median [25, 75 percentile] number of ACPA reactivities in
all patients was 9 [4, 12], and were most prevalent in anti-cyclic citrullinated peptide /rheumatoid factor-positive patients
10 [7, 12]. Disease activity measures and ultrasound scores at baseline were lower in ACPA reactivity-positive compared to
ACPA reactivity-negative patients. ACPA reactivity levels decreased after 3 months of DMARD treatment, most pronounced
for fibrinogenβ 60–74 to 62% of baseline antibody level, with least change in filaggrin 307–324 to 81% of baseline antibody
level, both p< 0.001. However, outcomes in disease activity measures, ultrasound and radiographic scores after 12 and
24 months were not associated with baseline levels or changes in ACPA reactivity levels and/or seroreversion after
3 months.
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Conclusions: The clinical relevance of analysing ACPA reactivities in intensively treated and closely monitored early RA was
limited, with no apparent associations with disease activity, prediction of treatment response or radiographic progression.
Further studies in larger patient materials are needed to understand the role of ACPA reactivities in patients with RA
classified according to the 2010 ACR/EULAR criteria and treated according to modern treatment strategies.
Trial registration: www.ClinicalTrials.gov, NCT01205854. Registered on 21 September 2010.
Keywords: Rheumatoid arthritis, Biomarkers, Inflammation, Imaging, Outcomes
Background
A high level of anti-citrullinated protein antibodies
(ACPA) is predictive of radiographic progression in
rheumatoid arthritis (RA) [1, 2], and ACPA positivity has
been associated with radiographic damage even before RA
onset [1] and in early RA [1, 3–7]. Positivity to the
anti-cyclic citrullinated peptide (anti-CCP2) test, hereafter
referred to as “anti-CCP”, reflects presence of antibodies
to mixed cyclic citrullinated peptides (i.e. ACPAs) as an
artificial mimic of the true autoantigens [8]. The ACPA
response against citrullinated antigens in RA, hereafter re-
ferred to as “ACPA reactivity”, has been shown to be het-
erogeneous [9–15]. Presence of ACPA reactivities may
precede the onset of anti-CCP positivity [16], as several
studies have shown that both the number of ACPA reac-
tivities and their individual titres increase before clinical
onset of RA [12, 13, 16–19].
RA patients may be characterised by distinct autoanti-
body profiles, as serum samples from the majority of
anti-CCP-positive patients react with one or more specific
citrullinated target proteins [12, 13, 16, 17, 20]. ACPA re-
activities have also been found in patients who are
anti-CCP negative [14, 15, 20–22]. Previous studies have
shown that the individual titre of selected ACPA reactiv-
ities, such as anti-citrullinated vimentin, declines signifi-
cantly after initiation of disease-modifying antirheumatic
drug (DMARD) treatment, while the presence of
anti-CCP antibodies remains stable over time [23, 24].
Higher numbers of specificities have been associated with
increased risk of relapse in patients with early RA, who
are in clinical remission and tapering DMARDs [25].
ACPA reactivity against citrullinated vimentin has been
proposed to be involved in the bone-destructive processes
in undifferentiated arthritis [26], early RA [23, 24, 26, 27]
and established RA [28]. In early RA, seroreversion of
citrullinated vimentin during the first 3 months of treat-
ment has been shown to be associated with significantly
less 2-year radiographic progression, compared with pa-
tients who remained positive [23]. However, the clinical
relevance of measuring ACPA reactivities to obtain prog-
nostic information on treatment response or radiographic
damage in early undifferentiated arthritis [22, 29–31] or
early RA [32] has not been established.
To our knowledge, the associations between individual
ACPA reactivities and disease characteristics have not
been studied in patients with early RA classified accord-
ing to the 2010 American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
criteria. The aim of this study was to assess the preva-
lence of selected baseline ACPA reactivities, and to in-
vestigate the association between ACPA reactivities and
disease activity, ultrasound findings, treatment response
and radiographic damage in an inception cohort of pa-
tients with early RA.
Methods
Design and setting of the study
We used data from the completed “Aiming for remission
in rheumatoid arthritis: a randomized trial examining
the benefit of ultrasound in a clinical tight control regi-
men” (the ARCTIC trial, NCT01205854) [33], a study
designed to assess whether incorporation of ultrasound
information into treatment decisions would lead to im-
proved patient outcomes. All patients were treated ac-
cording to a tight-control treat-to-target strategy, with
evaluation at baseline and 12 additional study visits dur-
ing the 2-year follow up. The treatment target was no
swollen joints and Disease Activity Score (DAS) < 1.6
[34], and in half of the patients an additional target was
no joints with disease activity demonstrated on power
Doppler ultrasound [33]. Core disease activity measures
were collected at each visit. Initial treatment consisted
of methotrexate monotherapy 15 mg/week escalating to
20 mg/week and prednisolone starting at 15 mg with
tapering to stop over 7 weeks. If the treatment target
was not achieved, treatment was intensified following a
predetermined treatment protocol, with escalation to
triple therapy and then biologic DMARDs (bDMARDs).
Swollen joints and/or joints with power Doppler ultra-
sound activity could be injected with triamcinolone
hexacetonide (up to a maximum of 80 mg per visit). As
clinical and radiographic outcomes of the two strategy
arms were similar after 2 years, in the current report
the data from the two arms were pooled and analysed
together.
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Patients and controls
In the ARCTIC trial [33], 230 DMARD-naïve patients
with early RA classified according to the 2010 ACR/
EULAR criteria were recruited at 11 Norwegian rheuma-
tology centres between September 2010 and April 2013.
The patients were 18–75 years of age with symptom dur-
ation less than 2 years from first patient-reported swollen
joint, and DMARD-naïve with indication for DMARD
treatment. For the current analyses, all patients with
follow-up biobank serum samples were selected (n = 217).
Controls were blood donors with similar characteristics to
the patients included in the study (age, gender and smok-
ing status (n = 94)). Serum samples were collected at each
visit and stored at - 70 °C. The study was approved by the
local ethics committee of the South-Eastern Norway
Regional Health Authority and was conducted in compli-
ance with the Declaration of Helsinki and the Inter-
national Conference on Harmonization Guidelines for
Good Clinical Practice. All patients provided written in-
formed consent.
Laboratory examinations
Analysis of 16 ACPA reactivities and the corresponding
native arginine-containing control peptides targeting
citrullinated peptides from fibrinogen (Fib), alpha-1 eno-
lase (citrullinated enolase peptide 1 (CEP-1)), vimentin
(Vim), filaggrin (Fil) and histone (H) was performed
using a multiplex chip-based assay based on the Immu-
noCAP ISAC system (Phadia AB, Uppsala, Sweden) [15,
20]. All samples from 0, 3, 12 and 24 months were ana-
lysed. ACPA reactivity titres (AU/ml) were considered
positive if above the 98-percentile of values in 619 sub-
jects without RA [20]. Erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) were analysed locally
by in-house standard methodology. Anti-CCP was ana-
lysed by fluorometric enzyme immunocapture assay
(FEIA) (positive if ≥ 10 IU/mL) and rheumatoid factor
(RF) by ELISA (positive if ≥ 25 IU/mL).
Clinical and imaging assessments
Clinical joint examination was performed using the 44
swollen joint count (SJC44) and Ritchie Articular Index
for tender joints [35]. Patients and physicians reported
the overall assessment of disease activity and pain on
visual analogue scales (VAS), range 0–100. The compos-
ite index DAS was calculated [34] and response accord-
ing to the EULAR criteria [36] and fulfillment of ACR/
EULAR Boolean remission criteria were evaluated [37].
Radiographic examinations of the hands and feet from
baseline, 12 and 24 months were scored according to
the van der Heijde modified Sharp score [38]. Scoring
was performed in chronological order by two trained
readers blinded to clinical information, and the average
of the two scores was used. Presence of erosive disease
was defined as van der Heijde modified Sharp erosion
score ≥ 3, in line with the definition suggested by a
EULAR task force [39]. Radiographic progression was
defined as a change in van der Heijde modified Sharp
total score of ≥ 2 units over 2 years, which is above the
smallest detectable change (1.94 units).
Ultrasound examination was performed according to a
validated semi-quantitative 32-joint protocol with scores
of 0–3, separately for grey scale synovitis and power
Doppler ultrasound [40]. Half the patients underwent
ultrasound examination at all visits, while the patients in
the conventional group were examined clinically at every
visit and by ultrasound at baseline, 12 and 24 months
[33]. Examiners were thoroughly trained and an atlas
was available for reference [40].
Statistical analysis
Baseline characteristics were compared using the
chi-square test, t test and Mann-Whitney U test, as ap-
propriate. Correlation between anti-CCP/ACPA reactiv-
ity levels and number of ACPA reactivities and disease
activity measures, ultrasound and radiography scores
were assessed using Spearman’s rank correlation coeffi-
cient. Spearman’s correlation was classified as very weak,
weak, moderate, strong or very strong [41]. Association
between number of ACPA reactivities and treatment re-
sponse was evaluated using the Mann-Whitney U test.
Association between anti-CCP/ACPA reactivity status
and continuous variables was evaluated by the
Mann-Whitney U test, and association with categorical
variables was assessed by the chi-square test. ACPA re-
activity median levels at baseline and follow-up visits
were compared by paired samples using the Wilcox test,
comparing each time point with the baseline level. A
p value <0.05 was considered statistically significant.
Statistical analyses were performed using Stata Statistical
Software, version 14 (StataCorp LLC, TX, USA) and R
Statistical Software, version 3.4.0 (copyright 2017, The R
Foundation for Statistical Computing).
Results
Patient characteristics
A total of 217 patients and 94 healthy controls were
included in the study. Baseline characteristics according
to autoantibody subgroups are provided in Table 1. Pres-
ence of ACPA reactivities was seen mainly in patients
positive for anti-CCP and RF (Table 1), but ACPA reac-
tivities also occurred more frequently in anti-CCP/RF
negative patients than in controls (0 (0, 1) vs. 0 (0, 0),
p = 0.050; Table 1, Fig. 1). The anti-CCP level significantly
correlated with the number of citrullinated antigens
recognised (r = 0.76, p < 0.0001). ACPA reactivity presence
in the RF-negative subset was generally higher than in the
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anti-CCP-negative group (Table 1). Among the 63
RF-negative patients, 31 were anti-CCP positive.
ACPA reactivities and disease activity at baseline
The DAS, SJC44 and ultrasound grey scale and power
Doppler scores were significantly higher in patients who
were negative for anti-CCP. Similarly, lack of the most
commonly occurring ACPA reactivities (Fibβ 60–74,
Vim 60–75 and H4 31–50) was associated with higher
DAS, SJC44 and ultrasound grey scale and power
Doppler to a statistically significant level (Table 2).
When performing the same analyses on the anti-CCP
positive cohort only, there were no differences in DAS,
SJC44 or ultrasound scores between the patients testing
positive versus negative for the ACPA reactivities
(Additional file 1: Table S1). The DAS, SJC44 and ultra-
sound grey scale and power Doppler scores were
negatively correlated with the majority of the ACPA re-
activity levels at baseline (Additional file 1: Table S2). This
association was not seen when considering the anti-C-
CP-positive cohort only (Additional file 1: Table S3).
Number of ACPA reactivities was not correlated
with ESR and CRP (data not shown).
Table 1 Baseline characteristics and anti-citrullinated protein antibody (ACPA) reactivities in subgroups of patients with rheumatoid

















Age, yearsa 51.5 (13.6) 50.8 (13.2) 55.0 (14.9) 51.9 (13.3) 50.8 (14.2) 51.7 (13.6) 55.0 (16.1) 52.1 (9.2)
Femaleb 131 (60) 109 (61) 22 (56) 91 (59) 40 (63) 86 (59) 17 (53) 57 (61)
Ever-smokerb 148 (68) 122 (69) 26 (67) 109 (71) 39 (62) 103 (70) 20 (62) 60 (64)
DASa 3.5 (1.2) 3.4 (1.1) 4.0 (1.3) 3.5 (1.2) 3.5 (1.2) 3.42 (1.1) 3.9 (1.2) NA
DAS28a 4.4 (1.2) 4.4 (1.2) 4.7 (1.2) 4.5 (1.2) 4.2 (1.3) 4.5 (1.1) 4.5 (1.1) NA
vdHSS totalc 4.0 [1.5, 8.0] 4.0 [1.5, 7.9] 4.5 [2.0, 10] 4.5 [2.0, 8.0] 3.5 [1.5, 10] 4.5 [2.0, 8.0] 5.5 [1.8, 12.8] NA
vdHSS erosionc 3.0 [1, 4.5] 3.0 [1, 4.5] 3.0 [1.0, 5.5] 3.0 [1.5, 4.5] 3.0 [1.0, 5.5] 3.0 [1.0, 4.5] 3.0 [1.0, 6.3] NA
vdHSS JSNc 1.0 [0.0, 3.0] 1.0 [0.0, 3.0] 1.5 [0.0, 5.0] 1.0 [0.0, 3.0] 1.0 [0.0, 3.0] 1.0 [0.0, 3.0] 1.5 [0.0, 6.5] NA
Ultrasound grey scalec 18 [10, 28] 16 [9, 24] 33 [20, 51] 17 [10, 26] 21 [12, 36] 16 [9, 25] 33 [21, 52] NA
Ultrasound power Dopplerc 7 [3, 14] 6 [2, 12] 14 [6, 28] 6 [2, 13] 8 [3, 15] 6 [2, 12] 13 [6, 29] NA
Number of ACPA reactivitiesc 9 [4, 12] 10 [7, 12] 0 [0, 1] 10 [7, 12] 2 [0, 10] 10 [7, 12] 0 [0, 1] 0 [0, 0]
ACPA reactivity status, n (%)
Fibβ 60-74cit 162 (75) 160 (90) 2 (5) 136 (88) 26 (41) 134 (91) 0 (0) 0 (0)
Vim 60-75cit 159 (73) 152 (85) 7 (18) 130 (84) 29 (46) 128 (87) 5 (16) 5 (5)
H4 31-50cit 145 (67) 142 (80) 3 (8) 119 (77) 26 (41) 118 (80) 2 (6) 1 (1)
CEP-1 140 (65) 137 (77) 3 (8) 117 (76) 23 (37) 115 (78) 1 (3) 1 (1)
Fil 307-324cit 136 (63) 134 (75) 2 (5) 113 (73) 23 (37) 112 (76) 1 (3) 0 (0)
Fibα 573cit 123 (57) 121 (68) 2 (5) 99 (64) 24 (38) 99 (67) 2 (6) 0 (0)
Fibβ 36-52cit 117 (54) 116 (65) 1 (3) 96 (62) 21 (33) 96 (65) 1 (3) 2 (2)
H3 1-30cit 107 (49) 106 (60) 1 (3) 93 (60) 14 (22) 92 (63) 0 (0) 0 (0)
H4 14-34cit 105 (48) 103 (58) 2 (5) 90 (58) 15 (24) 88 (60) 0 (0) 3 (3)
H3 21-44cit 96 (44) 94 (53) 2 (5) 80 (52) 16 (25) 79 (54) 1 (3) 1 (1)
Fibα 621-635cit 93 (43) 92 (52) 1 (3) 78 (51) 15 (24) 77 (52) 0 (0) 1 (1)
Vim 2-17cit 88 (41) 87 (49) 1 (3) 80 (52) 8 (13) 79 (54) 0 (0) 0 (0)
Fibα 36-50cit 79 (36) 79 (44) 0 (0) 67 (44) 12 (19) 67 (46) 0 (0) 0 (0)
Fibα 591cit 69 (32) 66 (37) 3 (8) 56 (36) 13 (21) 55 (37) 2 (6) 1 (1)
Fibβ 74cit 66 (30) 60 (34) 6 (15) 54 (35) 12 (19) 51 (35) 3 (9) 3 (3)
Fibβ 72cit 27 (12) 24 (13) 3 (8) 21 (14) 6 (1) 20 (14) 2 (6) 2 (2)
Abbreviations: RA rheumatoid arthritis; anti-CCP anti-cyclic citrullinated peptide, RF rheumatoid factor, DAS Disease Activity Score, vdHSS van der Heijde modified
Sharp score, JSN joint space narrowing, ACPA anti-citrullinated protein antibody, Fib fibrinogen, cit citrullinated, Vim vimentin, H histone, CEP-1 citrullinated enolase
peptide-1, Fil filaggrin; numbers referring to amino acid sequence, NA not applicable
aMean (SD)
bNumber (percentage)
cMedian [25, 75 percentile]
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ACPA reactivities and disease activity after initiation of
DMARD treatment
ACPA reactivity levels declined significantly after initi-
ation of DMARD treatment (Fig. 2a) with the most
prominent drop in ACPA reactivity levels occuring
within the first 3 months. The delta median change in
DAS (after 6, 12 and 24 months), ultrasound grey scale
and power Doppler (both after 12 and 24 months) was
higher in the ACPA reactivity negative patients, with few
exceptions (Table 3). However, these differences between
the ACPA reactivity negative versus positive patients in
DAS, ultrasound grey scale and power Doppler evened
out during follow up (data not shown). The most pro-
nounced relative change comparing baseline levels to
levels after 3 months was seen for Fibβ 60–74 and the
least marked decrease was for Fil 307–324 (38% vs. 19%
decrease, both p < 0.001; Fig. 2a). We wanted to investi-
gate whether the relative change in ACPA reactivity
levels after 3 months differed between patients with
lasting methotrexate treatment response and patients re-
quiring triple treatment and/or bDMARDs over the
2 years of follow up. A greater relative change after
3 months of DMARD treatment was seen in most ACPA
reactivities in patients who were methotrexate mono-
therapy responders, and to a statistically significant de-
gree for Vim 60–75 and H4 31–50 (Fig. 2b).
ACPA reactivities at baseline and prediction of treatment
response
There was no difference in median baseline level of the
individual ACPA reactivities (data not shown) or ba-
seline median number of ACPA reactivities between
patients with successful methotrexate monotherapy ac-
cording to EULAR good/moderate response and patients
with no treatment response after 3 months (9 [4, 12] vs.
10 [4, 11]; p = 0.80). Likewise, no difference was seen in
median baseline level of the individual ACPA reactivities
(data not shown) or median number of ACPA reacti-
vities in patients reaching remission vs. not reaching
remission according to DAS (8 [3, 12] vs. 10 [6, 12];
p = 0.16) or ACR/EULAR Boolean criteria (9 [4, 12]
vs. 9 [5, 11]; p = 0.74) after 6 months of methotrexate
treatment. Median baseline number of ACPA reacti-
vities for patients reaching vs. not reaching DAS re-
mission at 12 months was 8 [4, 11] vs. 10 [6, 11], p = 0.26
and for 24 months 8 [4, 12] vs. 10 [4, 11], p = 0.87. For
ACR EULAR Boolean remission at 12 months, the corre-
sponding numbers were 7 [3, 11] vs. 10 [5, 11], p = 0.08 and
at 24 months 8 [3, 11] vs. 9 [6, 12], p = 0.36, respectively.
When stratifying by number of ACPA reactivities,
there was a trend that patients with no ACPA reactivities
present at baseline were more likely to be in methotrex-
ate monotherapy remission according to DAS after 6
months than patients with 1-5, 6-8or ≥9 ACPA reacti-
vities present at baseline (70% vs. 53%, 53%, and 47%,
respectively; p = 0.18). No such trend was found for DAS
remission at 12 months (81% vs. 67%, 77% and 67%, re-
spectively; p = 0.50) or 24 months (89% vs. 85%, 78%,
and 78%, respectively; p = 0.71). When comparing the
proportion of patients in remission according to the
ACR/EULAR Boolean remission criteria in relation to
number of baseline ACPA reactivities, no trend was seen
at 6, 12 or 24 months (data not shown).
ACPA and radiographic damage
Anti-CCP positivity was not associated with baseline
radiographic scores, and neither of the individual ACPA
reactivity levels was associated with baseline radio-
graphic scores or baseline erosive disease (Table 2).
Overall median observed change in van der Heijde
modified Sharp total score after 12 and 24 months did
not differ between ACPA reactivity-positive vs.





Fig. 1 Number of anti-citrullinated protein antibody (ACPA)
reactivities according to autoantibody status. a All patients with
rheumatoid arthritis (RA). b Controls. c Patients with anti-cyclic
citrullinated peptide (anti-CCP)+ RA. d Patients with anti-CCP- RA. e
Patients with rheumatoid factor (RF)+ RA. f Patients with RF- RA. g
Patients with anti-CCP+/RF+ RA. h Patients with anti-CCP-/RF- RA
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and/or levels of any of the ACPA reactivities were not
associated with progression of radiographic damage or
change in radiographic score after 12 and 24 months,
and seroreversion of any ACPA reactivity after 3 months
of treatment was not associated with less radiographic
progression after 12 and 24 months (data not shown).
Outcomes did not differ when performing subanalyses
on the anti-CCP-positive cohort only. Number of ACPA
reactivities was not associated with baseline radiographic
scores or presence of baseline erosive disease (Table 4).
However, there was a trend towards less radiographic
progression after 12 and 24 months in patients with no
Table 2 Baseline disease characteristics (median values) in anti-CCP and ACPA reactivity-positive versus reactivity-negative patients
ESR CRP DAS SJC44 RAI US GS US PD vdHSS E vdHSS JSN vdHSS T
p p p p p p p p p p
Anti-CCP + (82%) 21 0.10 7 0.20 3.24 < 0.01 8 < 0.01 7 0.17 16 < 0.01 6 < 0.01 3 0.72 1 0.10 4 0.37
- (18%) 13 7 4.09 18 8 33 14 3 1.5 4.5
Fibβ 60–74 + (75%) 20 0.63 7 0.04 3.28 0.02 7 < 0.01 7 0.65 17 < 0.01 6 < 0.01 3 0.97 1 0.71 4.5 0.73
- (25%) 19 10 3.87 14 7 28 11 3 0.5 3.5
Vim 60–75 + (73%) 18 0.95 7 0.54 3.29 0.05 8 < 0.01 6 0.83 17 < 0.01 6 0.02 3 0.96 1 0.26 4.5 0.95
- (27%) 21 7 3.77 14 7 23 9 3 1 4
H4 31–50 + (67%) 21 0.39 8 0.65 3.27 0.01 8 < 0.01 6 0.03 17 0.01 6 0.01 3 0.88 1 0.94 4.5 0.70
- (33%) 17 7 3.84 13 10 21 9 3 0.75 3.25
CEP-1 + (65%) 21 0.13 8 0.93 3.32 0.35 9 0.06 7 0.47 17 0.03 6 0.12 3 0.76 1 0.46 4.5 0.54
- (35%) 17 6 3.36 11 7 21 7 3 0.5 3.5
Fil 307–324 + (63%) 21 0.15 8 0.70 3.29 0.06 7 < 0.01 7 0.54 17 0.01 6 < 0.01 3 0.94 1 0.98 4 0.91
- (37%) 17 7 3.64 13 7 21 9 3 1 4
Fibα 573 + (57%) 22 0.13 8 0.85 3.27 0.03 7 < 0.01 6 0.14 17 0.05 6 0.12 3 0.61 1 0.23 4.5 0.37
- (43%) 16 7 3.42 12 8 21 8 3 0.5 4
Fibβ 36–52 + (54%) 21 0.08 8 0.78 3.26 0.05 8 < 0.01 6 0.06 17 0.06 6 0.03 3 0.58 1 0.05 4.5 0.19
- (46%) 17 7 3.63 11 8 19 8 3 0.5 3.5
H3 1–30 + (49%) 18 0.97 7 0.40 3.29 0.48 8 0.09 6 1.00 17 0.04 6 0.09 3 0.62 0.5 0.04 4 0.16
- (51%) 20 7 3.37 10 7 19 7 3 1 4.5
H4 14–34 + (48%) 21 0.13 8 0.74 3.27 0.28 7 < 0.01 7 0.77 17 0.30 7 0.86 3 0.39 1 0.30 4 0.28
- (52%) 18 7 3.45 11 7 20 6 3 1 4.5
H3 21–44 + (44%) 22 0.09 9 0.21 3.31 0.69 9 0.07 7 0.84 17 0.28 6 0.41 3 0.68 0.5 0.14 4 0.32
- (56%) 18 6 3.36 10 7 19 7 3 1 4.5
Fibα 621–635 + (43%) 22 0.36 8 0.84 3.29 0.09 7 < 0.01 7 0.54 16 0.02 6 0.07 2.5 0.46 0.5 0.30 4 0.34
- (57%) 18 7 3.37 12 7 20 7 3 1 4.5
Vim 2–17 + (41%) 19 0.72 7 0.49 3.29 0.34 7 < 0.01 7 0.48 17 0.08 6 0.13 3 0.50 1 0.61 4 0.45
- (59%) 20 7 3.36 11 7 20 7 3 1 4
Fibα 36–50 + (36%) 20 0.73 8 0.86 3.29 0.68 8 0.04 7 0.46 17 0.08 6 0.05 3 0.84 0.5 0.29 4 0.59
- (64%) 19 7 3.41 11 7 19 7 3 1 4
Fibα 591 + (32%) 19 0.70 6 0.29 3.29 0.05 7 < 0.01 6 0.28 17 0.53 6 0.88 3 0.86 1 0.33 4.5 0.70
- (68%) 20 8 3.40 11 7 19 7 3 0.5 4
Fibβ 74 + (30%) 22 0.19 8 0.87 3.25 0.53 9 0.12 8 0.74 17 0.08 6 0.67 2.5 0.57 0.5 0.32 4 0.48
- (70%) 18 7 3.33 10 7 19 7 3 1 4
Fibβ 72 + (12%) 21 0.25 5 0.59 3.59 0.37 10 0.48 9 0.52 22 0.19 9 0.06 3 0.73 0.5 0.72 4 0.98
- (88%) 19 7 3.31 9 7 17 6 3 1 4
Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: p values (p) were derived from the Mann-Whitney U test;
statistically significant differences are in italics
Abbreviations: ESR erythrocyte sedimentation rate (millimetre/hour, 1–140), CRP C-reactive protein (milligram/litre), DAS Disease Activity Score (0–10), SJC swollen
joint count (0–44), RAI Ritchie articular index (0–78), US ultrasound, GS grey scale (0–96), PD power Doppler (0–96), vdHSS van der Heijde modified Sharp score,
E erosion (0–280), JSN joint space narrowing (0–168), T total (0–448), anti-CCP anti-cyclic citrullinated peptide, Fib fibrinogen, Vim vimentin, H histone, CEP-1 citrullinated
enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence
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baseline ACPA reactivities compared with 1–5, 6–8 and
≥ 9 reactivities (Fig. 3), and also when comparing no base-
line ACPA reactivities with ≥ 1 reactivities (21% vs. 39% at
12 months, p = 0.10 and 33% vs. 39% at 24 months,
p = 0.66).
Discussion
To our knowledge, this is the first study to examine the
relationship between ACPA reactivities in patients with
early RA classified according to the 2010 ACR/EULAR
criteria and imaging and serological and clinical disease
activity measures, and their potential use in prediction
of treatment response and radiographic progression [42].
The prevalence of ACPA reactivities was associated with
anti-CCP/RF positivity, and baseline disease activity
measures and ultrasound scores were lower in ACPA
reactivity-positive compared to ACPA reactivity-negative
patients. ACPA reactivity levels decreased after initiation
of DMARD treatment, but the clinical implications of
measuring ACPA reactivities to predict treatment re-
sponse and radiographic progression in this cohort of in-
tensively treated patients with early RA were limited.
High levels of anti-CCP antibodies have previously
been shown to be a risk factor for erosive disease [1, 2],
and selected ACPA reactivities have also been shown to
be associated with osteoclast activation and radiographic
damage [23, 24, 26, 27, 43]. Kastbom et al. have shown
that ACPA reactivity levels declined after 3 months of
methotrexate treatment, and that disappearance of cer-
tain ACPA reactivities was associated with less 2-year
radiographic progression [23]. In our study, levels of all
ACPA reactivities declined after 3 months of DMARD
treatment. None of the individual ACPA reactivities ana-
lysed were associated with baseline erosive disease or
radiographic progression, nor was seroreversion of indi-
vidual ACPA reactivities associated with less radio-
graphic progression over the 2 years of follow up in our
study. Presence, but not titre, of reactivities to citrulli-
nated fibrinogen was associated with faster joint destruc-
tion in the ESPOIR cohort of patients with very early
RA fulfilling either the 1987 ACR criteria at inclusion or
the 2010 ACR/EULAR criteria within 3 years of inclu-
sion [26]. We identified a trend that patients with ≥ 1
ACPA reactivity at baseline experienced more radio-
graphic progression at 12 and 24 months compared to
patients with no ACPA reactivities present, but the find-
ings were not significant. Lack of significant association
between number of ACPA reactivities and radiographic
progression has previously also been described in the
Leiden early arthritis cohort where patients fulfilled the
1987 ACR criteria within 1 year after inclusion [29–31].
Previous studies have not demonstrated association
between the individual ACPA reactivities and disease
activity measures in early undifferentiated arthritis and
early RA [29–32]. ACPA reactivities present in anti-
CCP-negative patients with RA have not been shown to
be associated with clinical or prognostic parameters [22].
As previously published, seropositive patients in the
ARCTIC cohort had significantly lower disease activity
compared to seronegative patients [44], similar to what
has been reported in other cohorts [45, 46]. The most
prevalent ACPA reactivities in our study were negatively
correlated with the DAS, SJC44 and ultrasound grey
scale and power Doppler scores at baseline, and the dis-
ease activity measurements were numerically higher in
patients who were negative for the individual ACPA re-
activities, which has not been described previously.
These differences were no longer present when exclu-
ding the anti-CCP-negative subgroup and are thus po-
tentially a consequence of the 2010 ACR/EULAR
a
b
Fig. 2 Relative change in levels of various anti-citrullinated protein
antibody (ACPA) reactivities in patients with early rheumatoid
arthritis (RA) (only baseline seropositive patients included) a Relative
change between baseline and 3, 12 and 24 months, b Relative
change after 3 months, comparing patients on methotrexate
monotherapy at 24 months (n = 113) to patients on triple and/or
biological disease-modifying antirheumatic drugs (bDMARDs) at
24 months (n = 82). Fib, fibrinogen; Vim, vimentin; H, histone;
CEP-1, citrullinated enolase peptide-1; Fil, Filaggrin, numbers
referring to amino acid sequence
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classification criteria, where the anti-CCP/RF-negative
patients require greater joint involvement than the sero-
positive patients to fulfill the criteria [42, 44].
Current guidelines for treat-to-target emphasise the
importance of improvement in disease activity within
3 months (EULAR good/moderate response) and at-
tainment of the treatment target (ACR/EULAR Boolean
remission) within 6 months after initiating treatment
[47]. A greater decrease in ACPA reactivity levels has
been demonstrated in treatment responders compared
to non-responders [23]. In our cohort we identified a
similar trend whereby reduction in ACPA reactivity
levels after 3 months was more pronounced in patients
remaining on methotrexate monotherapy after 2 years
of follow up, but we did not observe any baseline pre-
dictors of treatment response.



















p p p p p p p p p
Fibβ 60–74 + −1.9 0.04 −2.0 < 0.01 − 2. 0 0.02 − 12 < 0.01 − 13 < 0.01 −6 < 0.01 − 6 < 0.01 0.5 0.92 1.0 0.69
– − 2.5 −2.6 −2.6 − 19 −21 −9 −10 0.5 1.0
Vim 60–75 + −1.9 < 0.01 − 1.9 < 0.01 − 2.0 0.02 − 12 < 0.01 − 13 < 0.01 − 6 0.06 − 6 0.02 0.5 0.59 1.0 0.68
– −2.6 − 2.6 − 2.6 −17 − 17 −8 −8 0.5 1.0
H4 31–50 + −1.9 < 0.01 − 1.9 < 0.01 −2.0 < 0.01 − 12 0.05 − 13 < 0.01 − 6 0.08 − 6 0.02 0.5 0.15 1.0 0.81
– −2.5 − 2.8 − 2.7 − 15 −17 −7 −8 0.5 1.0
CEP-1 + −2.0 0.75 − 2.1 0.79 −2.1 0.48 −12 0.23 − 14 0.24 −6 0.17 −6 0.14 0.5 0.50 1.0 0.41
– −2.1 −2.2 −2.0 −14 −14 −7 − 7 0.5 1.0
Fil 307–324 + −1.9 0.01 −1.8 < 0.01 − 1.9 0.01 − 12 0.06 − 13 0.01 −6 0.03 −5 0.01 0.5 0.75 1.0 0.76
– −2.4 −2.5 −2.5 −16 −16 −7 − 7 0.5 1.0
Fibα 573 + −1.9 < 0.01 −1.8 < 0.01 − 1.9 < 0.01 − 13 0.36 − 14 0.12 −6 0.21 −6 0.08 0.5 0.89 1.0 0.77
– −2.5 −2.6 −2.4 −13 −15 −7 −7 0.5 1.5
Fibβ 36–52 + −1.9 0.02 −1.9 < 0.01 − 1.9 < 0.01 −12 0.23 −14 0.09 −6 0.08 −5 0.02 0.5 0.89 1.0 0.58
– −2.4 −2.5 −2.5 −14 − 14 −7 −7 0.5 1.5
H3 1–30 + −2.1 0.97 − 2.2 0.97 − 2.0 0.44 −12 0.31 − 13 0.04 −6 0.25 −6 0.09 0.5 0.24 1.0 0.45
– −2.0 −2.1 −2.2 −14 −16 −7 −7 0.5 1.2
H4 14–34 + −1.9 0.07 −2.0 0.12 −2.0 0.14 −12 0.46 −12 0.02 −7 0.63 −6 0.54 0.5 0.32 1.5 0.10
– −2.1 −2.3 −2.2 −14 −16 −6 −6 0.5 1.0
H3 21–44 + −2.0 0.48 −2.0 0.31 −2.0 0.37 −12 0.29 −13 0.39 −6 0.28 −6 0.38 0.5 0.39 1.5 0.76
– −2.0 −2.2 −2.2 −15 −15 −7 −7 0.5 1.0
Fibα 621–635 + −1.7 0.04 −1.8 0.04 −1.9 0.03 −11 0.02 −13 0.01 −6 0.09 −6 0.05 0.5 0.20 1.0 0.22
– −2.3 −2.4 −2.2 −15 −16 −7 −7 0.5 1.5
Vim 2–17 + −1.9 0.04 −1.8 0.02 −1.8 0.01 −12 0.12 −12 < 0.01 −6 0.21 −5 0.04 0.5 0.90 1.0 0.87
– −2.2 −2.3 −2.3 −14 −16 −7 −7 0.5 1.0
Fibα 36–50 + −2.0 0.83 − 2.0 0.74 − 2.0 0.45 −11 0.09 − 12 0.10 −5 0.02 −5 0.02 0.5 0.61 1.0 0.52
– −2.0 −2.2 −2.2 −14 −15 −7 −7 0.5 1.0
Fibα 591 + −1.9 0.08 − 1.8 0.03 − 1.8 0.01 − 13 0.69 − 16 0.70 −6 0.84 −6 0.77 0.5 0.41 1.0 0.58
– −2.2 −2.3 −2.3 −13 −14 −6 −7 0.5 1.5
Fibβ 74 + −1.8 0.41 −2.0 0.79 −2.1 0.55 −12 0.36 −13 0.94 −7 0.82 −7 0.98 0.5 0.06 1.5 0.54
– −2.1 −2.2. −2.0 −13 −14 −6 −6 0.5 1.0
Fibβ 72 + −2.0 0.84 −2.0 0.73 −1.9 0.78 − 16 0.19 − 17 0.21 −7 0.13 −9 0.11 0.2 0.98 0.5 0.51
– −2.0 −2.2. −2.1 −12 −14 −6 −6 0.5 1.0
Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: p values (p) were derived from the Mann-Whitney U test;
statistically significant differences are in italics
Abbreviations: DAS Disease Activity Score (0–10), SJC swollen joint count (0–44), US ultrasound, GS grey scale (0–96), PD power Doppler 0–96), vdHSS van der Heijde
modified Sharp score, T total (0–448), Fib fibrinogen, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino
acid sequence
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Comparison between our results and those of other
studies may be limited by the fact that patients in most
previous studies were classified by the 1987 ACR criteria
or in cohorts of patients treated less intensively. The
relatively few anti-CCP-negative patients in comparison
with the larger amount of anti-CCP positive patients re-
flects an effect of implementing the 2010 ACR/EULAR
classification criteria [33] and in this study, the number
of patients in the subgroups of anti-CCP and ACPA
reactivity-negative patients is somewhat small for mean-
ingful comparisons. When applying the 2010 ACR/
EULAR criteria as inclusion criteria, the seronegative pa-
tients included in the study were required to have more
joint involvement with > 10 clinically involved joints
[42]. Patients with a clinical seronegative RA diagnosis
involving fewer joints were not included. Strengths of
the study were that all patients were classified by the
2010 ACR/EULAR criteria, were DMARD and cortico-
steroid naïve at inclusion and were treated according to
a standardised treatment protocol adhering to current
treatment recommendations [33]. The treatment regi-
men of the ARCTIC trial is well in line with current
EULAR recommendations for treatment of early RA
[47]. Such intensive treatment may suppress the RA dis-
ease activity to such a degree that prognostic markers
identified in previous less strictly controlled RA cohorts
may no longer be present or of clinical relevance. The
current study was also strengthened by a relatively large
sample size and a broad collection of serological, clinical
and imaging data.
Conclusions
New classification criteria and modern intensive treat-
ment strategies have altered the disease course of early
RA, and consequently established predictors for treat-
ment response and progression of radiographic damage
should be re-evaluated in appropriate cohorts. In this in-
ception cohort of RA patients classified according to the
ACR/EULAR 2010 criteria, the prevalence of ACPA re-
activities differed in subgroups according to anti-CCP
and RF status, and ACPA reactivity levels decreased after
initiation of DMARD treatment. There were no apparent
associations with disease activity, prediction of treatment
response or radiographic progression, and further stud-
ies in larger patient samples are needed to understand
the role of ACPA reactivities in patients with RA classi-
fied according to the 2010 ACR/EULAR criteria.
Additional file
Additional file 1: Table S1. Disease characteristics (median values) in
ACPA reactivity-positive versus reactivity-negative patients in the anti-
CCP-positive sub-group (n = 178); p values were derived from the Mann-
Whitney U test and statistically significant differences are marked in bold.
Reactivities are sorted by decreasing frequency in the cohort. Table S2.
Correlation between ACPA reactivities and disease activity (baseline).
Spearman correlation (p value). Table S3. Correlation between reactivities
and disease activity in anti-CCP-positive patients (baseline). Spearman
correlation (p value). (DOCX 41 kb)
Abbreviations
ACPA: Anti-citrullinated protein antibody; ACR: American College of
Rheumatology; Anti-CCP: Anti-cyclic citrullinated peptide; ARCTIC: Aiming for
remission in rheumatoid arthritis: a randomized trial examining the benefit of
ultrasound in a clinical tight control regimen; AU: Accredited units;
bDMARDs: Biologic disease-modifying antirheumatic drug; CEP-1: Citrullinated
Table 4 Association between number of baseline ACPA reactivities and van der Heijde modified Sharp scores (erosion, joint space
narrowing and total) and association between number of baseline ACPA reactivities and baseline erosive disease











vdHSS erosiona 3.0 [1.0, 5.8] 3.0 [1.5, 4.0] 3.0 [2.0, 4.0] 3.0 [1.0, 4.5] 0.87
vdHSS joint space narrowinga 1.5 [0.0, 4.8] 0.5 [0.0, 2.0] 0.5 [0.0, 3.0] 1.0 [0.0, 3.8] 0.54
vdHSS totala 3.0 [1.5, 11.2] 3.5 [1.5, 6.0] 4.5 [2.5, 7.0] 4.2 [1.5, 9.0] 0.83
Erosive diseaseb 15 (56) 21 (54) 21 (57) 60 (53) 0.97
Abbreviations: ACPA Anti-citrullinated protein antibody, vdHSS van der Heijde modified Sharp score
aMedian [25,75 percentile]
bNumber (percentage)
Fig. 3 Proportion of patients with radiographic progression by number
of baseline ACPA reactivities after 12 months (n= 199) and
24 months (n= 195)
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enolase peptide-1; CRP: C-reactive protein; DAS: Disease Activity Score;
DMARD: Disease-modifying antirheumatic drug; E: Erosion; ELISA: Enzyme-linked
immunosorbent assay; ESR: Erythrocyte sedimentation rate; EULAR: European
League Against Rheumatism; FEIA: Fluorometric enzyme immunocapture assay;
Fib: Fibrinogen; Fil: Filaggrin; H: Histone; JSN: Joint space narrowing;
mL: Milliliter; RA: Rheumatoid arthritis; RAI: Ritchie Articular Index;
RF: Rheumatoid factor; SJC: Swollen joint count; T: Total; VAS: Visual analogue
scale; vdHSS: van der Heijde modified Sharp score; Vim: Vimentin
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